Conjugation of EGFR-specific peptides to the surface of anticancer drug-loaded nanoparticles could be a more effective therapeutic strategy focusing on drug delivery to mesenchymal TNBC tumor masses. The gene discussed is EGFR; the disease is neoplasm.